Celltrion Reveals Positive Clinical Trial Data for Biosimilar Adalimumab

Celltrion Healthcare has revealed positive one-year results from a Phase III trial comparing biosimilar adalimumab, Yuflyma, with the reference adalimumab in patients with rheumatoid arthritis.